Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Tanios Bekaii‐Saab, Rona Yaeger, Alexander I. Spira, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 25, pp. 4097-4106
Open Access | Times Cited: 140

Showing 26-50 of 140 citing articles:

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Elena Brozos-Vázquez, Marta Toledano‐Fonseca, Nicolás Costa‐Fraga, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102719-102719
Open Access | Times Cited: 6
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
Birgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Cancer Discovery (2024) Vol. 15, Iss. 1, pp. 119-138
Open Access | Times Cited: 6
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Hossam Nada, Yongseok Choi, Sung-Do Kim, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
Doaa Bugazia, Ebtesam Al-Najjar, Abdullah Esmail, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
The Landmark Series: The Future of Pancreatic Cancer Clinical Trials
Yongwoo David Seo, Matthew H. G. Katz, Rebecca A. Snyder
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2777-2785
Closed Access
Update for: New developments in systemic therapy for advanced biliary tract cancer
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer.
Sara Raji, Hamed Zaribafzadeh, Tyler Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics
Xiaoqiang Cui, Teng Huang, Tianyi Jiang, et al.
Cancer Letters (2025) Vol. 614, pp. 217540-217540
Closed Access
A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer
Saskia Hussung, Dilara Akhoundova, Clelia Pistoni, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 7, pp. 100134-100134
Closed Access
Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review
Umar Hayat, Phillip Croce, Aseel Saadeh, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1129-1129
Open Access
Multidisciplinary Therapeutic Approaches to Pancreatic Cancer According to the Resectability Status
Aurelio Mauro, Carlotta Faverio, L. Brizzi, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1167-1167
Open Access
How I Treat Advanced Biliary Cancer
Arathi Mohan, Vaibhav Sahai
Advances in Oncology (2025)
Closed Access
Pancreatic Ductal Adenocarcinoma (PDAC): Clinical Progress in the Last Five Years
Osama Mosalem, Ahmed Abdelhakeem, Nayef Hikmat Abdel-Razeq, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-12
Closed Access
Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database
Zheng Shi, Yu Xia, Yifan Zhao, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results
Stefan Kasper, Martin Sebastian
Deutsches Ärzteblatt international (2025)
Closed Access
Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
Khalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Clinical Cancer Research (2025) Vol. 31, Iss. 5, pp. 899-906
Closed Access
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access
Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
Krishnan K. Mahadevan, Antonio Maldonado, Bingrui Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Overview on biomarkers for immune oncology drugs
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Diagnostik und Therapiekonzepte für das Pankreaskarzinom – Update 2024
Angelika Kestler, Thomas Seufferlein
Gastroenterologie up2date (2025) Vol. 21, Iss. 01, pp. 25-41
Closed Access
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers
Peter F. Gallagher, Christian Rolfo, Elena Élez, et al.
BJC Reports (2025) Vol. 3, Iss. 1
Open Access
KRAS Mutations in Cancer
Yuan‐Zhu Zhang, Yujie Ma, Kexin Zhang, et al.
American Journal of Clinical Oncology (2025)
Closed Access

Scroll to top